MA32899B1 - Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine - Google Patents
Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabineInfo
- Publication number
- MA32899B1 MA32899B1 MA33941A MA33941A MA32899B1 MA 32899 B1 MA32899 B1 MA 32899B1 MA 33941 A MA33941 A MA 33941A MA 33941 A MA33941 A MA 33941A MA 32899 B1 MA32899 B1 MA 32899B1
- Authority
- MA
- Morocco
- Prior art keywords
- cytarabine
- recognize
- formulations containing
- containing antibodies
- cancer formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Abstract
La présente invention concerne une composition pharmaceutique comprenant un anticorps reconnaissant spécifiquement CD38 et de la cytarabine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08291118A EP2191842A1 (fr) | 2008-11-28 | 2008-11-28 | Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine |
| PCT/IB2009/055391 WO2010061359A1 (fr) | 2008-11-28 | 2009-11-27 | Associations antitumorales contenant des anticorps reconnaissant spécifiquement cd38 et de la cytarabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32899B1 true MA32899B1 (fr) | 2011-12-01 |
Family
ID=40627502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33941A MA32899B1 (fr) | 2008-11-28 | 2011-06-13 | Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US20120093806A1 (fr) |
| EP (2) | EP2191842A1 (fr) |
| JP (2) | JP2012510463A (fr) |
| KR (1) | KR101715958B1 (fr) |
| CN (2) | CN102264386A (fr) |
| AR (1) | AR073425A1 (fr) |
| AU (1) | AU2009321251B2 (fr) |
| BR (1) | BRPI0921858B1 (fr) |
| CA (1) | CA2745005C (fr) |
| CL (1) | CL2011001232A1 (fr) |
| CO (1) | CO6440556A2 (fr) |
| CR (1) | CR20110282A (fr) |
| DK (1) | DK2370096T5 (fr) |
| EA (1) | EA027070B1 (fr) |
| EC (1) | ECSP11011071A (fr) |
| ES (1) | ES2638926T3 (fr) |
| HN (1) | HN2011001423A (fr) |
| HR (1) | HRP20171301T1 (fr) |
| HU (1) | HUE035910T2 (fr) |
| IL (2) | IL213118A (fr) |
| LT (1) | LT2370096T (fr) |
| MA (1) | MA32899B1 (fr) |
| MX (1) | MX344973B (fr) |
| NI (1) | NI201100107A (fr) |
| NZ (1) | NZ593085A (fr) |
| PA (1) | PA8849901A1 (fr) |
| PE (1) | PE20120205A1 (fr) |
| PL (1) | PL2370096T3 (fr) |
| PT (1) | PT2370096T (fr) |
| PY (1) | PY09043372A (fr) |
| RS (1) | RS56248B1 (fr) |
| SG (1) | SG171821A1 (fr) |
| SI (1) | SI2370096T1 (fr) |
| SM (1) | SMT201700403T1 (fr) |
| TN (1) | TN2011000242A1 (fr) |
| TW (1) | TWI436770B (fr) |
| UA (1) | UA104160C2 (fr) |
| UY (1) | UY32266A (fr) |
| WO (1) | WO2010061359A1 (fr) |
| ZA (1) | ZA201104064B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2191842A1 (fr) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine |
| NZ607473A (en) | 2010-09-27 | 2014-11-28 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| ES2658953T3 (es) | 2012-09-25 | 2018-03-13 | Morphosys Ag | Combinaciones y usos de los mismos |
| JP6279065B2 (ja) * | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
| EP3063173B1 (fr) * | 2013-10-31 | 2020-07-29 | Sanofi | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| CA2986594C (fr) | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anticorps anti-cd38 pour le traitement de l’amyloïdose à chaînes légères et d’autres tumeurs malignes hématologiques positives à cd38 |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| CN108450004A (zh) * | 2015-09-14 | 2018-08-24 | 白血病治疗有限责任公司 | 通过调节RhoH来鉴定新的诊断和治疗 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3484923A1 (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| WO2019035938A1 (fr) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| US12371506B2 (en) | 2018-01-12 | 2025-07-29 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of anti-CD38 antibodies |
| JP7687956B2 (ja) | 2019-03-15 | 2025-06-03 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| TW202606756A (zh) | 2019-12-05 | 2026-02-16 | 美商賽諾菲阿凡提斯美國有限責任公司 | 用於皮下投予之抗cd38抗體的調配物 |
| CA3204187A1 (fr) | 2021-01-14 | 2022-07-21 | Stefan Steidl | Anticorps anti-cd38 et leurs utilisations |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| CN113278075B (zh) * | 2021-06-18 | 2021-12-14 | 芜湖森爱驰生物科技有限公司 | 一种炎症检测试剂盒 |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP0822830B1 (fr) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Anticorps anti-IL-8 dérivés de xenosouris immunisées |
| WO1996034096A1 (fr) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| TR199902553T2 (xx) | 1997-04-14 | 2000-03-21 | Micromet Gesellschaft F�R Biomedizinische Forschung Mbh | �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2003524587A (ja) * | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| EP3312196B1 (fr) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Anticorps dirigés contre cd38 pour le traitement du myélome multiple |
| AU2007302448C1 (en) * | 2006-09-26 | 2019-02-14 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| EP1914242A1 (fr) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
| EP2245065A1 (fr) * | 2008-01-23 | 2010-11-03 | Xencor, Inc. | Anticorps dirigés contre cd40 optimisés et leurs procédés d'utilisation |
| EP2191842A1 (fr) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine |
-
2008
- 2008-11-28 EP EP08291118A patent/EP2191842A1/fr not_active Ceased
-
2009
- 2009-11-25 TW TW098140152A patent/TWI436770B/zh active
- 2009-11-25 AR ARP090104547A patent/AR073425A1/es not_active Application Discontinuation
- 2009-11-25 PY PY200909043372A patent/PY09043372A/es unknown
- 2009-11-25 UY UY0001032266A patent/UY32266A/es not_active Application Discontinuation
- 2009-11-25 PA PA20098849901A patent/PA8849901A1/es unknown
- 2009-11-27 SG SG2011037975A patent/SG171821A1/en unknown
- 2009-11-27 CN CN2009801481843A patent/CN102264386A/zh active Pending
- 2009-11-27 LT LTEP09775304.0T patent/LT2370096T/lt unknown
- 2009-11-27 CA CA2745005A patent/CA2745005C/fr not_active Expired - Fee Related
- 2009-11-27 AU AU2009321251A patent/AU2009321251B2/en active Active
- 2009-11-27 JP JP2011538094A patent/JP2012510463A/ja not_active Withdrawn
- 2009-11-27 SM SM20170403T patent/SMT201700403T1/it unknown
- 2009-11-27 WO PCT/IB2009/055391 patent/WO2010061359A1/fr not_active Ceased
- 2009-11-27 EP EP09775304.0A patent/EP2370096B1/fr active Active
- 2009-11-27 UA UAA201108055A patent/UA104160C2/uk unknown
- 2009-11-27 EA EA201100868A patent/EA027070B1/ru not_active IP Right Cessation
- 2009-11-27 BR BRPI0921858-0A patent/BRPI0921858B1/pt active IP Right Grant
- 2009-11-27 KR KR1020117014748A patent/KR101715958B1/ko active Active
- 2009-11-27 SI SI200931726T patent/SI2370096T1/sl unknown
- 2009-11-27 DK DK09775304.0T patent/DK2370096T5/en active
- 2009-11-27 NZ NZ593085A patent/NZ593085A/xx not_active IP Right Cessation
- 2009-11-27 HR HRP20171301TT patent/HRP20171301T1/hr unknown
- 2009-11-27 MX MX2011005666A patent/MX344973B/es active IP Right Grant
- 2009-11-27 US US13/130,867 patent/US20120093806A1/en not_active Abandoned
- 2009-11-27 ES ES09775304.0T patent/ES2638926T3/es active Active
- 2009-11-27 RS RS20170860A patent/RS56248B1/sr unknown
- 2009-11-27 CN CN201710103901.7A patent/CN107096022A/zh active Pending
- 2009-11-27 HU HUE09775304A patent/HUE035910T2/en unknown
- 2009-11-27 PT PT97753040T patent/PT2370096T/pt unknown
- 2009-11-27 PL PL09775304T patent/PL2370096T3/pl unknown
- 2009-11-27 PE PE2011001097A patent/PE20120205A1/es not_active Application Discontinuation
-
2011
- 2011-05-17 TN TN2011000242A patent/TN2011000242A1/fr unknown
- 2011-05-23 EC EC2011011071A patent/ECSP11011071A/es unknown
- 2011-05-24 IL IL213118A patent/IL213118A/en active IP Right Grant
- 2011-05-24 IL IL213115A patent/IL213115A/en active IP Right Grant
- 2011-05-26 CL CL2011001232A patent/CL2011001232A1/es unknown
- 2011-05-26 CR CR20110282A patent/CR20110282A/es unknown
- 2011-05-27 NI NI201100107A patent/NI201100107A/es unknown
- 2011-05-27 CO CO11065641A patent/CO6440556A2/es unknown
- 2011-05-27 HN HN2011001423A patent/HN2011001423A/es unknown
- 2011-06-01 ZA ZA2011/04064A patent/ZA201104064B/en unknown
- 2011-06-13 MA MA33941A patent/MA32899B1/fr unknown
-
2015
- 2015-06-01 JP JP2015111127A patent/JP6072854B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32895B1 (fr) | Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et de la vincristine | |
| MA30345B1 (fr) | Formulation d'anticorps monoclonal humain anti-igf-1r | |
| MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
| ECSP11011071A (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| MA34816B1 (fr) | Combinaisons antitumorales contenant des anticorps reconnaissant specifiquement le cd38 et du bortezomib | |
| MA32894B1 (fr) | Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide | |
| MA29369B1 (fr) | Dosage fixe d'anticorps anti-her | |
| MA30497B1 (fr) | Anticorps et immunco-conjugues, et leurs utilisations. | |
| MY158560A (en) | Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof | |
| MA33213B1 (fr) | Anticorps antagoniste specifique d'un heterodimere alpha-4-beta-7 | |
| SG10201914119TA (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| MA35009B1 (fr) | Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci | |
| MA44334A (fr) | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll | |
| MA30945B1 (fr) | Anticorps anti-tat226 et immunoconjugués | |
| MA33892B1 (fr) | Anticorps anti-her3, et leurs utilisations | |
| MY164577A (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan | |
| MA30531B1 (fr) | Anticorps anti-dll4 et leurs procedes d'utilisation | |
| MY171841A (en) | Antibody formulation | |
| MA33537B1 (fr) | Anticorps anti-cdcp1 humanisés | |
| MA45450B1 (fr) | Formulations d'anticorps anti-cd19 | |
| DK1694706T3 (da) | Modificeret anti-CD52-antistof | |
| CR10555A (es) | Vacunas para malaria | |
| MA34541B1 (fr) | Compositions d'anticorps et procédés d'utilisation | |
| CL2012002948A1 (es) | Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado. | |
| PH12013500432A1 (en) | Anti-vegfr-3 antibody compositions |